PANTOPRAZOLE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H15F2N3O4S
Molecular Weight	383.3715
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COc1ccnc(CS(=O)c2nc3ccc(cc3[nH]2)OC(F)F)c1OC

InChI

InChIKey=IQPSEEYGBUAQFF-UHFFFAOYSA-N

InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)

HIDE SMILES / InChI

Molecular Formula	C16H15F2N3O4S
Molecular Weight	383.3715
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

Pantoprazole is a proton pump inhibitor that inhibits gastric acid secretion and used for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease. Pantoprazole suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours. Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus for adults and pediatric patients 5 years of age and older caused by gastroesophageal reflux disease. It can be used as a maintenance therapy for long-term use after initial response is obtained, but there have not been any controlled studies about the use of pantoprazole past a duration of 12 months. Pantoprazole may also be used in combination with antibiotics to treat ulcers caused by Helicobacter pylori. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 20 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18536934 \| https://www.ncbi.nlm.nih.gov/pubmed/8389196	Inhibitor 3315
Potassium-transporting ATPase 20 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11402494	Inhibitor 3315

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erosive esophagitis associated with gastroesophageal reflux disease 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 4033	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 9.7182718E11
Zollinger-Ellison syndrome 10 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 4033	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 9.7182718E11

C_max

Value	Dose	Co-administered	Analyte	Population
2.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 753 inducer 374 substrate 882	substrate 530 inhibitor 825	substrate 610 inhibitor 894

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP2 184 OAT3 290 CYP2C8 417 CYP1A2 725 CYP2A6 334 CYP2E1 424 P-gp 666 BCRP 303 CYP2C19 700 OAT1 279 OATP1B1 369 OATP1B3 319 OCT1 254 OCT2 297 OCT3 82 ALDH1 20 MATE2 126 MATE1 143 OATP2B1 66	CYP2C19 500 P-gp 724 sulfotransferases 15	CYP1A 31 CYP1A1 67 CYP2C 8

Drug as perpetrator

Target	Modality	Activity
ALDH1 20	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	inconclusive [Activation 22.3872 uM]
OATP1B1 379	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/19139163/	likely
CYP1A2 805	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6Ilx0Q0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 356	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP2D6 908	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 467	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP3A4 920	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
MATE2 126	inhibitor 1612 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >500 uM]
CYP2C8 448	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	no
MRP2 239	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	no
OATP2B1 67	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
CYP2C19 738	inhibitor 1612 Sources: https://go.drugbank.com/drugs/DB00213 \| https://drug-interactions.medicine.iu.edu/MainTable.aspx \| https://pubmed.ncbi.nlm.nih.gov/21795468/	weak [IC50 93 uM]
P-gp 754	inhibitor 1612 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes [IC50 17.9 uM]
OCT2 298	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 2.8 uM]
OCT3 82	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 22.9 uM]
OCT1 266	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 30.8 uM]
OAT3 291	inhibitor 1612 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 4.45 uM]
MATE1 145	inhibitor 1612 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	yes [IC50 43.2 uM]
BCRP 346	inhibitor 1612 Sources: https://go.drugbank.com/articles/A16380 \| https://pubmed.ncbi.nlm.nih.gov/19076159/	yes [IC50 5.5 uM]
OAT1 280	inhibitor 1612 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 63.21 uM]
CYP2C9 851	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/15258107/	yes [Ki 6.5 uM]
CYP1A 63	inducer 772 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=21 Page: (Pharm_P7) 21	yes
CYP1A1 108	inducer 772 Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/	yes
CYP2C 18	inducer 772 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
CYP3A4 920	inducer 772 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
MRP2 239	activator 106 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	yes
OATP1B3 326	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OCT3 82	activator 106 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes

Drug as victim

Target	Modality	Activity
CYP2C19 500	substrate 1689 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29346&ns=ncit&type=relationship&key=n75796996&b=1&n=0&vse=null Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP3A4 882	substrate 1689 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP2C9 530	substrate 1689 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
CYP2D6 610	substrate 1689 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
P-gp 724	substrate 1689 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes
sulfotransferases 15	substrate 1689 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=102625707 \| https://pubmed.ncbi.nlm.nih.gov/9165689/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7915	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7915
ChemicalBook	CB51025809	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51025809
ChemicalBook	CB8129842	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8129842
MolPort	MolPort-003-666-752	https://www.molport.com/shop/molecule-link/MolPort-003-666-752
MolPort	MolPort-005-933-577	https://www.molport.com/shop/molecule-link/MolPort-005-933-577
eMolecules	902267	https://www.emolecules.com/cgi-bin/more?vid=902267

PubMed

Title	Date	PubMed
Lansoprazole: an update of its place in the management of acid-related disorders.	2001	11693467
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.	2001 Aug	11558857
Dyspepsia: challenges in diagnosis and selection of treatment.	2001 Aug	11558854
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.	2001 Aug	11507354
Resolution of Menetrier's disease after Helicobacter pylori eradication therapy.	2001 Aug 24	11589437
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.	2001 Dec	11770010
Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia.	2001 Dec	11736723
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.	2001 Jul	11519776
Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration.	2001 Jul	11488838
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.	2001 Jul	11474311
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole.	2001 Jul	11421879
[Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma].	2001 Jul-Aug	11475787
Shortcomings of the first-generation proton pump inhibitors.	2001 May	11430506
A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.	2001 Nov	11683695
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.	2001 Oct	11695354
Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis.	2001 Oct	11563998
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.	2001 Sep	11552908
[Comparative study of proton pump inhibitors].	2001 Sep 9	11680100
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].	2002	12353402
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.	2002	12222994
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.	2002	12060043
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].	2002	12043311
Selective colonization by Helicobacter pylori of the deep gastric glands and intracellular canaliculi of parietal cells in the setting of chronic proton pump inhibitor use.	2002 Apr	11943964
Pantoprazole IV (Protonix IV).	2002 Apr 29	11981511
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.	2002 Aug	12182745
[Proton pump inhibitors: Pantoprazole].	2002 Feb	11979865
Nonallergic anaphylaxis to pantoprazole.	2002 Feb	11929432
The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.	2002 Jan	11743248
Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography.	2002 Jan 5	11824393
Gateways to clinical trials.	2002 Jan-Feb	11980386
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.	2002 Jul	12177723
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.	2002 Jul	12152007
Proton pump inhibitors: an update.	2002 Jul 15	12152963
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.	2002 Jul 15	12119060
Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.	2002 Jul-Aug	12143188
Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study.	2002 Jul-Aug	12115018
Pantoprazole-induced recurrent anaphylactic shock.	2002 Jun	12094902
Intravenous proton pump inhibitors in the critical care setting.	2002 Jun	12072664
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.	2002 Jun	12072662
Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.	2002 Jun	12072661
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.	2002 Jun	12072599
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.	2002 Jun	12030958
[Correlation of Barrett's esophagus and colonic adenomas].	2002 Jun 9	12132329
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.	2002 Mar	11876710
Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.	2002 May	12017345
Combination drug therapy for gastroesophageal reflux disease.	2002 May	11978171
Stability of pantoprazole in an extemporaneously compounded oral liquid.	2002 May 15	12040734
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.	2002 Oct	12352294
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.	2002 Oct 21	12381251
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.	2002 Sep	12395996

Patents

Sample Use Guides

In Vivo Use Guide

Oral use: Short-Term Treatment of Erosive Esophagitis Associated With GERD: 40 mg Once daily for up to 8 weeks; Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: 40 mg Twice daily IV: The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days

Route of Administration: Other

In Vitro Use Guide

To determine "ex vivo" gastric mucosa gastric acid secretion, pantoprazole (as DMSO solution diluted with serosal fluid) was added to membrane mucosa liquid in the bath tube. Pantoprazole final concentration in serosal fluidwas 5 mkM, incubation time -- 2.5h. Pantoprazole mediated gastric acid secretion inhibition is 24.3% at 5mkM.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 22:01:15 UTC 2021` Edited by `admin` on `Fri Jun 25 22:01:15 UTC 2021`
Record UNII	D8TST4O562
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PANTOPRAZOLE

Official Name

English

PANTOPRAZOLE [HSDB]

Common Name

English

5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE

Systematic Name

English

ZOVANTA

Brand Name

English

PANTOPRAZOLE [WHO-DD]

Common Name

English

PANTOPRAZOLE [VANDF]

Common Name

English

BY-1023

Code

English

PANTOPRAZOLE [MART.]

Common Name

English

PANTOZOL

Brand Name

English

PANTOCID

Brand Name

English

PANTOPRAZOLE [INN]

Common Name

English

SK&F-96022

Code

English

(+/-)-PANTOPRAZOLE

Common Name

English

2-(((3,4-DIMETHOXYPYRIDIN-2-YL)METHYL)SULFINYL)-5-DIFLUOROMETHOXY-1H-BENZIMIDAZOLE

Systematic Name

English

BY 1023

Code

English

1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-

Systematic Name

English

5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)BENZIMIDAZOLE

Systematic Name

English

NSC-759257

Code

English

ALTOPAN

Common Name

English

PANTOPRAZOLE [MI]

Common Name

English

PANTOPRAZOLE [EMA EPAR]

Common Name

English

6-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE

Systematic Name

English

PANTOLOC

Brand Name

English

SKF-96022

Code

English

PANTOPRAZOLE [USAN]

Common Name

English

1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)-

Systematic Name

English

SK&F 96022

Code

English

Classification Tree Code System Code

NDF-RT

N0000175525